PARP inhibition in BRCA2-mutated prostate cancer
Defects in DNA repair genes are increasingly recognized as a defining molecular feature of a subset of patients with prostate cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to have clinical activity in this subgroup, but other compounds including platinum also warrant explora...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 28, Heft: 1, Pages: 189-191 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw445 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1093/annonc/mdw445 Verlag, Volltext: https://academic.oup.com/annonc/article/28/1/189/2669812 
|
| Verfasserangaben: | C. Nientiedt, Y. Tolstov, A.-L. Volckmar, V. Endris, D. Bonekamp, U. Haberkorn, D. Jäger, H. Sültmann, A. Stenzinger, M. Hohenfellner, C. Grüllich, S. Duensing |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1577772709 | ||
| 003 | DE-627 | ||
| 005 | 20220814194732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180719r20172016xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdw445 |2 doi | |
| 035 | |a (DE-627)1577772709 | ||
| 035 | |a (DE-576)507772709 | ||
| 035 | |a (DE-599)BSZ507772709 | ||
| 035 | |a (OCoLC)1341014030 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Nientiedt, Cathleen |e VerfasserIn |0 (DE-588)1162095288 |0 (DE-627)1025532813 |0 (DE-576)507145070 |4 aut | |
| 245 | 1 | 0 | |a PARP inhibition in BRCA2-mutated prostate cancer |c C. Nientiedt, Y. Tolstov, A.-L. Volckmar, V. Endris, D. Bonekamp, U. Haberkorn, D. Jäger, H. Sültmann, A. Stenzinger, M. Hohenfellner, C. Grüllich, S. Duensing |
| 264 | 1 | |c 2017 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online 29 September 2016 | ||
| 500 | |a Gesehen am 19.07.2018 | ||
| 520 | |a Defects in DNA repair genes are increasingly recognized as a defining molecular feature of a subset of patients with prostate cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to have clinical activity in this subgroup, but other compounds including platinum also warrant exploration. We report here the remarkable clinical course of a patient with a germline BRCA2 mutation treated with the PARP inhibitor olaparib. | ||
| 534 | |c 2016 | ||
| 700 | 1 | |a Tolstov, Yanis |e VerfasserIn |0 (DE-588)1075655714 |0 (DE-627)833614746 |0 (DE-576)444443320 |4 aut | |
| 700 | 1 | |a Volckmar, Anna-Lena |d 1984- |e VerfasserIn |0 (DE-588)173874916 |0 (DE-627)698776666 |0 (DE-576)134713478 |4 aut | |
| 700 | 1 | |a Endris, Volker |e VerfasserIn |0 (DE-588)1063753686 |0 (DE-627)812590961 |0 (DE-576)422898198 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Hohenfellner, Markus |d 1958- |e VerfasserIn |0 (DE-588)133862518 |0 (DE-627)557857988 |0 (DE-576)300155263 |4 aut | |
| 700 | 1 | |a Grüllich, Carsten |d 1965- |e VerfasserIn |0 (DE-588)14101914X |0 (DE-627)624500985 |0 (DE-576)321797981 |4 aut | |
| 700 | 1 | |a Duensing, Stefan |d 1967- |e VerfasserIn |0 (DE-588)1074044487 |0 (DE-627)830213007 |0 (DE-576)435550098 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 28(2017), 1, Seite 189-191 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a PARP inhibition in BRCA2-mutated prostate cancer |
| 773 | 1 | 8 | |g volume:28 |g year:2017 |g number:1 |g pages:189-191 |g extent:3 |a PARP inhibition in BRCA2-mutated prostate cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdw445 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/28/1/189/2669812 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180719 | ||
| 993 | |a Editorial | ||
| 994 | |a 2017 | ||
| 998 | |g 1074044487 |a Duensing, Stefan |m 1074044487:Duensing, Stefan |d 910000 |d 910200 |e 910000PD1074044487 |e 910200PD1074044487 |k 0/910000/ |k 1/910000/910200/ |p 12 |y j | ||
| 998 | |g 14101914X |a Grüllich, Carsten |m 14101914X:Grüllich, Carsten |d 910000 |d 910100 |e 910000PG14101914X |e 910100PG14101914X |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 133862518 |a Hohenfellner, Markus |m 133862518:Hohenfellner, Markus |d 910000 |d 910200 |e 910000PH133862518 |e 910200PH133862518 |k 0/910000/ |k 1/910000/910200/ |p 10 | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |e 910000PS139606106 |e 912000PS139606106 |k 0/910000/ |k 1/910000/912000/ |p 9 | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 7 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 6 | ||
| 998 | |g 1063753686 |a Endris, Volker |m 1063753686:Endris, Volker |d 910000 |d 912000 |e 910000PE1063753686 |e 912000PE1063753686 |k 0/910000/ |k 1/910000/912000/ |p 4 | ||
| 998 | |g 173874916 |a Volckmar, Anna-Lena |m 173874916:Volckmar, Anna-Lena |d 910000 |d 912000 |e 910000PV173874916 |e 912000PV173874916 |k 0/910000/ |k 1/910000/912000/ |p 3 | ||
| 998 | |g 1075655714 |a Tolstov, Yanis |m 1075655714:Tolstov, Yanis |d 910000 |d 910200 |e 910000PT1075655714 |e 910200PT1075655714 |k 0/910000/ |k 1/910000/910200/ |p 2 | ||
| 998 | |g 1162095288 |a Nientiedt, Cathleen |m 1162095288:Nientiedt, Cathleen |d 910000 |d 910100 |e 910000PN1162095288 |e 910100PN1162095288 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1577772709 |e 3018347951 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1577772709","physDesc":[{"extent":"3 S."}],"relHost":[{"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"pubHistory":["1.1990 -"],"id":{"zdb":["2003498-2"],"issn":["1569-8041"],"eki":["320428796"]},"part":{"year":"2017","volume":"28","pages":"189-191","issue":"1","text":"28(2017), 1, Seite 189-191","extent":"3"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320428796","disp":"PARP inhibition in BRCA2-mutated prostate cancerAnnals of oncology","origin":[{"publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"title":[{"subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology","title":"Annals of oncology"}]}],"person":[{"family":"Nientiedt","role":"aut","given":"Cathleen","display":"Nientiedt, Cathleen"},{"given":"Yanis","role":"aut","family":"Tolstov","display":"Tolstov, Yanis"},{"display":"Volckmar, Anna-Lena","role":"aut","given":"Anna-Lena","family":"Volckmar"},{"display":"Endris, Volker","family":"Endris","given":"Volker","role":"aut"},{"family":"Haberkorn","given":"Uwe","role":"aut","display":"Haberkorn, Uwe"},{"role":"aut","given":"Dirk","family":"Jäger","display":"Jäger, Dirk"},{"display":"Stenzinger, Albrecht","role":"aut","given":"Albrecht","family":"Stenzinger"},{"display":"Hohenfellner, Markus","family":"Hohenfellner","role":"aut","given":"Markus"},{"given":"Carsten","role":"aut","family":"Grüllich","display":"Grüllich, Carsten"},{"display":"Duensing, Stefan","family":"Duensing","role":"aut","given":"Stefan"}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}],"title":[{"title_sort":"PARP inhibition in BRCA2-mutated prostate cancer","title":"PARP inhibition in BRCA2-mutated prostate cancer"}],"note":["Published online 29 September 2016","Gesehen am 19.07.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"name":{"displayForm":["C. Nientiedt, Y. Tolstov, A.-L. Volckmar, V. Endris, D. Bonekamp, U. Haberkorn, D. Jäger, H. Sültmann, A. Stenzinger, M. Hohenfellner, C. Grüllich, S. Duensing"]},"id":{"eki":["1577772709"],"doi":["10.1093/annonc/mdw445"]}} | ||
| SRT | |a NIENTIEDTCPARPINHIBI2017 | ||